相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys
Eugene Y. Tan et al.
DRUG METABOLISM AND DISPOSITION (2010)
Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans
Sanjeev Kumar et al.
DRUG METABOLISM AND DISPOSITION (2010)
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Evan A. Stein et al.
EUROPEAN HEART JOURNAL (2010)
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing
Michael Derks et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effect of Hepatic Impairment on the Pharmacokinetics of Dalcetrapib
Mary Phelan et al.
Journal of Clinical Lipidology (2010)
Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug-Drug Interactions
Michael Derks et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Biochemical characterization of cholesteryl ester transfer protein inhibitors
Mollie Ranalletta et al.
JOURNAL OF LIPID RESEARCH (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2009)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Daniel Bloomfield et al.
AMERICAN HEART JOURNAL (2009)
The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors
Menno Vergeer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Safety and Tolerability of Dalcetrapib
Evan A. Stein et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Rajesh Krishna et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Rajesh Krishna et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A Single-Center, Open-Label, One-Sequence Study of Dalcetrapib Coadministered With Ketoconazole, and an In Vitro Study of the S-Methyl Metabolite of Dalcetrapib
Michael Derks et al.
CLINICAL THERAPEUTICS (2009)
In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates
Michael Derks et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers
Rajesh Krishna et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
R. Krishna et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Philip Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease
Prediman K. Shah
EUROPEAN HEART JOURNAL (2007)
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
RW Clark et al.
JOURNAL OF LIPID RESEARCH (2006)
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
M. John Chapman
PHARMACOLOGY & THERAPEUTICS (2006)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials
RS Birjmohun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia
RJ Bisoendial et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
ME Brousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib
RW Clark et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans
CC Schwartz et al.
JOURNAL OF LIPID RESEARCH (2004)
A review of CETP and its relation to atherosclerosis
GJ de Grooth et al.
JOURNAL OF LIPID RESEARCH (2004)
HDL: The metabolism, function, and therapeutic importance
MH Wang et al.
CHEMICAL REVIEWS (2004)
Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals
H Okamoto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
SJ Robins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors - The prospective pravastatin pooling project
FM Sacks et al.
CIRCULATION (2000)
分享论文
